Delivery Order SPE2DB24D2205-SPE2DB25FEHRA
- Not listed
- The Defense Logistics Agency awarded a $1,288.86 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. The contract, which is not set-aside and was competitively awarded, has an ultimate completion date of August 4, 2025, with performance to be executed at the awardee's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,718.48 and is scheduled for completion by September 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action under a larger vehicle, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Envarsus XR 1 mg tablets (100-count) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract is structured as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units, with a contract ceiling value of $1,718.48. This firm fixed-price delivery order, with an ultimate completion date of October 1, 2025, represents a non-set-aside competitive award to support federal medical procurement requirements. The award is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,288.86 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count packaging). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle supporting military healthcare programs globally through December 2026....
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $5,135.85 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,711.95 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg on August 4, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract represents a pharmaceutical supply delivery executed under a competitively awarded vehicle. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) valued at $1,711.95. This competitively awarded, non-set-aside delivery order carries a firm fixed price and is scheduled for completion by October 6, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a $1,288.86 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Envarsus XR 1 mg tablets (100-count package), with an ultimate completion date of August 12, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with the federal government. The product will be delivered to the company's...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHRADelivery Order
The Defense Logistics Agency awarded a $2,577.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Envarsus XR 1 mg tablets (100-unit quantity), with an ultimate completion date of October 7, 2025. This non-set-aside competitive award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's role under the broader DLA pharmaceutical prime vendor program enables it to supply an extensive portfolio of medications, vaccines, and medical supplies across multiple therapeutic domains to support military operations and veteran healthcare worldwide. This specific delivery order for Envarsus XR, an immunosuppressive medication, exemplifies the company's ongoing role in fulfilling specialized pharmaceutical requirements for the federal government through the competitive contracting process.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 9/16/25 |